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In the kidney, low-molecular-weight proteins (LMWPs) are
relatively freely filtered and after reabsorption by the proximal
tubular cells, intracellularly catabolized into small peptides and
single amino acids [1]. As such, the kidney plays an important
role in the elimination of circulating LMWPs. Studies aimed at
quantifying the renal contribution to catabolism of LMWPs
revealed rather variable results. On the one hand a major, if not
exclusive, renal contribution (60 to 90%) to the total clearance
was claimed on the basis of the renal extraction measurements
of the particular LMWP [2—4]. On the other hand, several
studies showed a considerable lower renal contribution (30 to
60%), calculated on the basis of the actual amount of adminis-
tered LMWP measured in the kidneys [6—10]. The question is
whether methodological differences can explain the observed
discrepancies. With regard to the renal rate of degradation,
large differences have been found for individual LMWPs.
Previous studies on this topic were performed either in vitro
kidney preparations [2, 3, 7, 11], or by measuring the renal
LMWP concentration in extirpated kidneys at different time
intervals [7, 8]. The disadvantage of the latter in vivo studies is
the low time resolution. Bianchi et al introduced an elegant
non-invasive technique with a high time resolution with which
an indication of the renal degradation of a LMWP was obtained
[9'.
In the present study we studied the renal handling of the three
LMWPs cytochrome-c (Cy), lysozyme (Ly) and aprotinin (Ap),
chosen on the basis of their alleged difference in renal half life
[9]. We used a technique based on that previously reported by
Bianchi et al in which the renal handling of a radiolabeled
LMWP was monitored by external counting in the intact rat [9].
We modified this technique to enable quantification of both
renal uptake and degradation of a '231-labeled LMWP. To
validate the renal uptake data obtained with the '231-LMWP, we
used a second label, 1311-tyramine-cellobiose (TC), a radiolabel
that is retained within the cell in which it is internalized.
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Methods
Materials
Cytochrome-c (horse heart; molecular wt 12,400; p1 10.6),
lysozyme (egg white; molecular wt 14,300; p111) and aprotinin
(bovine lung; molecular wt 6,500; p110.5) were obtained from
Sigma (Axel, The Netherlands).
Experimental set-up
One week before the experiments, fma1e Wistar rats were
instrumented with a permanent venous heart cannula [12]. The
day before the experiment, the animals were fasted overnight
and received 2 mg sodium-iodine intravenously to minimize the
accumulation of unbound iodine in the thyroid glands and
stomach [13]. Anesthesia was induced with halothane and a
single dose of 30 mg/kg pentobarbital. During the experiment,
anesthesia was maintained by continuous infusion of 4 mg/kg/hr
pentobarbital. In addition, the rats received a continuous infu-
sion of 5% glucose (2.0 ml/hr) to induce a stable urine produc-
tion and 6 mg/hr 3-monoiodo-l-tyrosine (MIT) to saturate the
deiodinases [14]. Three rats were properly fixed on a middle-
energy collimator of a gamma camera. A window was selected
on the peak energy of 1231 and 131j with a width of 150 and 250
keV, respectively. Body temperature was monitored and main-
tained on 38°C with a heating pad and a lamp. Urine was
collected continuously via a short cannula in the urinary blad-
der, draining into a tube situated on the collimator. The urine
tube was exchanged after a half or one hour collection time.
After a stabilization of one hour, 1.1 MBq '231-LMWP was
co-injected with 0.55 MBq '311-TC-LMWP intravenously. The
gamma camera recorded the activity of both iodine isotopes in
one or five minute time frames for three to eight hours,
depending on the LMWP studied. The radioactivity time course
of the right kidney, urine and total body was subsequently
plotted after analysis of the respective "regions of interest."
The amount of radioactive iodine within the total body in the
first five minutes after injection was assumed to be 100% of the
injected dose. Blood and urine samples were taken to measure
the ratio of protein bound, amino acid bound or unbound
radioactivity. For each studied LMWP six rats were analyzed.
1231LMWP synthesis
'23ILMWP labeling was performed according to the chlora-
mine-T method of Hunter and Greenwood [15]. In short, 50 d
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protein (10 mg/mi) and 10 jd chioramine-T (5 mg/mi) were added
to 37 MBq Na'23! in 100 i phosphate buffer (0.2 M, pH 7.4) and
mixed for 60 seconds. The reaction was stopped by addition of
25 d metabisulfite (2.5 mg/mi). Free iodine was removed by a
separation on a Sephadex G25 column. The protein fraction was
used within two hours. Just before administration, 95% (Cy),
95% (Ly) and 94% (Ap) of the iodine were protein bound.
'311-TC-LMWP
Synthesis of tyramine-ceilobiose (TC) was performed by the
reductive amination of ceilobiose with tyramine [16, 171. In
short, 10 mmol cellobiose, 10 mmol tyramine hydrochloride and
10 mmoi propionic acid were dissolved in 40 ml methanol.
Sodium cyanoborohydride (12 mmol) was dissolved in 15 ml
methanol and added drop-wise. The mixture was refluxed
overnight. Acetone (300 ml) was added and the precipitate was
filtered. The precipitate was dissoived in water overnight and
appiied to a cation exchange column (Dowex W50-X4; size 0.25
x 20 cm). The column was eluted with 0.5 M ammonia and the
absorbance measured at 279 nm. The first peak was collected
and lyophilized twice in order to remove traces of ammonia.
The yield was about 40%.
'311-TC labeling and subsequently coupling to LMWP was
also carried out according to the method of Hysing and Tolle-
shaug [16], the modified version of Pittman et a! [17]. In short,
in an iodogen-coated tube, 10 jil tyramine-cellobiose (TC) (0.01
M) in phosphate buffer (0.02 M, pH 7.2) and 92 MBq Na'31! were
incubated for 30 minutes at room temperature. The reaction
was stopped by the addition of 10 p1 sodiumsulfite (0.05 M) and
5 p1 potassium-iodine (0.1 M). The solution was transferred to a
clean tube to couple the iodinated TC to the LMWP. Cyanuric
chloride (30 nmol) in 20 pi acetone and 5 p1 NaOH (0.01 M)
were added. After mixing for 30 seconds, 10 pi LMWP (100
mg/mi) in carbonate buffer (0.01 M, pH 9) was added and the
131ITCLMWP complex was separated from free compounds
on a Sephadex G25 column. The protein fraction appeared to be
very stable and was used within 40 hours. Just before adminis-
tration, 100% (Cy), 100% (Ly) and 99% (Ap) of the iodine was
protein bound.
Blood and urine analysis
The nature of the radioactive compounds in blood and urine
samples was determined according to the method of Albert and
Raymond Keating [18], slightly modified for analyzing small
samples. In short, the LMWP coupled radiolabel in urine was
measured by a trichloroacetic acid (TCA) precipitation of the
LMWP. Urine (100 p1) and 400 p1 0.5% bovine serum albumin
(BSA) were added to 250 p1 TCA (15% TCA, 0.1% Na!, 0.1%
tyrosine). After a high speed centrilugation of one minute the
precipitate was washed with 200 p1 1 M NaOH, to remove
co-precipitated free iodine, and reprecipitated with 300 p1 TCA.
After centrifugation, the radioactivity in the precipitate repre-
sented the LMWP coupled iodine. The TCA soluble radioac-
tivity was subsequently analyzed for amino acid coupled and
free iodine. The TCA supernatant was diluted with p1 32%
NaOH and Congo red, to change the solution to a basic
environment. Addition of 10 p1 50% HNO3 and subsequently
250 pl 10% AgNO3 in 2% HNO3, was performed for the
crystallization of the free iodine with silver. After centrifuga-
tion, the crystals were discarded to prevent interferences with
the counting of radioactivity. The radioactivity in the superna-
tant represents the amino acid bound iodine. The unbound
iodine could be calculated from the difference between radio-
activity in the untreated urine sample and the protein plus
amino acid fractions. The procedure for plasma samples was
the same except for the first step: 10 p1 plasma and 400 /Ll 0.35%
BSA were added to 250 tl TCA. Radiolabeled aprotinin ap-
peared to be TCA-precipitable for only 50%. The rest was
recovered in the unbound iodine fraction after Ag! crystalliza-
tion. The administered cytochrome-c and lysozyme were ana-
lyzed likewise. The protein fraction of the administered aproti-
nm was analyzed by thin layer chromatography.
Quantification of the gamma camera data
The data on radioactivity of the 123J and 131j measured over
the different regions in the rat by external counting had to be
transformed to the actual amount of label within the organ. To
enable this, we studied the following biasing parameters: (1) the
degree of scattering of the gamma emittance by surrounding
tissue, (2) the spillover of 131j pulses into the 123j channel, and
(3) the background. The relative contribution of these factors
was measured in a phantom rat model with the dimensions
similar to the in vivo situation. A plastic tank (19 x 9 x 2 cm3),
representing the total body of the rat, held two artificial plastic
kidneys (1.3 cm3 x 0.5 cm) and a urine tube of 1 ml, the average
volume present in the in vivo experiment. The different com-
partments were filled with saline and various concentrations of
123! or 131J Different sizes of the regions of interest were
analyzed for the iodine radioactivity. This resulted in the
following corrections for the in vivo experiments. For the 123J,
the region of the total body and urine tube contained the same
amount of radioactivity compared to the total field of the
camera. To estimate the total amount of '231-radioactivity
present in the right kidney, a region of interest was needed with
a size twice as large as the actual kidney. No corrections were
needed for the background or the scattering effect of the
radioactivity present in the left kidney. The counting efficiency
of the ''i appeared to be much lower. The total body and urine
tube region contained 80%, whereas the 2 cm2 sized right
kidney region only comprised 47% of the total field radioactiv-
ity. Furthermore, a correction was made for the spillover of 131!
pulses into the 123j channel. This spillover appeared to be 35%
for the kidney and 50% for the total body and urine tube. No
corrections were needed for background or scattering. To
ensure that indeed no background corrections were needed, we
studied the effect of an estimated background on the renal
time-activity curve of '23I-cytochrome-c (the LMWP that will
be mostly effected). This process did not have a major impact
on the results since the rates of degradation of the 1231
cytochrome-c were not changed significantly. To validate
whether the corrections of the 1311 gamma camera data were
justified in the in vivo studies with the combination of both
radiolabels, we compared the renal uptake of '311-TC-lysozyme
and 1231-TC-lysozyme in two separate in vivo experiments. The
renal uptake appeared to be similar which proves that the 131!
corrections estimated from the phantom model experiment are
indeed valid for the in vivo situation.
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Fig. 1. Plasma radioactivity as a function of
time after the intravenous injection of 123j and
'311-TC radiolabeled cytochrome-c (left
panels), lysozyme (middle panels) and
aprotinin (right panels) in the rat. Panels A.
Plasma disappearance of '3I-LMWPs (solid
line) and '311-TC-LMWPs (dotted line),
measured as TCA precipitable radioactivity.
Panels B. Plasma appearance of the 123J
degradation products (solid line) and '311-TC-
degradation products (dotted line) as the TCA
soluble radioactivity. Values are given as
mean + SEM [Note: the SEM of the plasma
concentration LMWP (panels A) is not visible
since the SEM falls within the size of the
marker].
Pharmacokinetic and statistical analysis
The pharmacokinetic analysis of the plasma and kidney
time-activity curves was performed using a computer program
for non-linear curve-fitting, MultiFit (Department of Pharma-
cology and Therapeutics, University of Groningen), using the
simplex algorithm [19]. Initial parameter estimates are automat-
ically obtained by a curve-stripping procedure. The reciprocal
of the y-value predicted by the model was used as the weighing
factor [20].
All data are expressed as mean SEM. Statistical analysis
was performed with the Wilcoxon rank test.
Results
Plasma disappearance of the radiolabeled LMWPs
After the intravenous injection of the 123J and 1311-TC radio-
labeled LMWPs cytochrome-c, lysozyme and aprotinin, the
plasma disappearance was determined by measuring the TCA
precipitable plasma radioactivity in time (Fig. 1A). The results
show that for each LMWP a similar biphasic plasma disappear-
ance pattern was found for the two labels, 1231 and 131-TC
(Table 1). Apparently, the difference in the two labels did not
affect the plasma elimination of the LMWP. Interestingly,
compared to one another, the distribution volume, estimated
from the second phase of the plasma disappearance, is mark-
edly different: 11 ml for cytochrome-c, 20 ml for lysozyme, and
50 ml for aprotinin.
Renal 123j time-course
The body distribution of the radiolabel 1231 was monitored
continuously by external counting. Following the intravenous
injection, a large amount of the '231-LMWP is directly taken up
by the kidney. After this first pass uptake, the renal uptake
continues gradually in combination with a degradation of the
LMWP in the kidney. Kinetic data of renal uptake and degra-
dation were obtained by computer-aided kinetic analysis. Fig-
ure 2 shows the renal time-course of the three 123J radiolabeled
LMWPs: cytochrome-c, lysozyme and aprotinin. Furthermore,
the regression lines are drawn which represent the renal rate of
uptake (a) and degradation (b). The results (Table 2) show that
Table 1. Plasma disappearance of radiolabeled LMWPs after
intravenous injection in the rat
Plasma half-life mm
Phase 1231 '311-TC-
LMWP (%) LMWP LMWP
Cytochrome-c 1st (94)
2" (6)
2.1, 2.4
133, 167
2.4, 2.8
90, 127
(N = 2)
Lysozyme 1St (94)
2°"(6)
2.6 0.3
180± 23
3.0 0.2
259±17
(N = 4)
Aprotinin 1St (96)
2"" (4)
2.0 0.2
657 62
1.9 0.2
646 126
(N = 5)
Data are given as mean SEM, except for cytochrome-c where the
results of both experiments are separately given. The values in paren-
thesis denote the contribution of the two phases relative to the total
plasma disappearance. The first phase represents the distribution and
first pass elimination of the LMWP from the plasma, the second phase
the plasma elimination.
the rate of renal uptake as well as degradation is very different
for the three LMWPs. Lysozyme is taken up and degraded
twice as fast as aprotinin. Cytochrome-c's rate of uptake is
eight times higher while the majority degrades 40 times faster
than aprotinin. To verify that 123J degradation products were
not retained within the kidney, thus obscuring our degradation
analyses, we measured the amount of 1231 bound to lysozyme in
extirpated kidneys. At the end of the experiment, 84 2%
(N 3) of the 1231 in the kidney appeared to be bound to
lysozyme. This is in agreement with other studies [1, 6] which
show that at least 85% of renal radioactivity is protein bound,
independent of the analysis time after injection.
Renal 131j time-course
The renal time-course of the 1311-TC-LMWPs was also re-
corded by external counting. After the first pass uptake, the
renal uptake continues gradually until a plateau level is reached
(Fig. 2). This plateau level very likely represents the total
amount of the LMWP that accumulates in the kidney, since the
'311-TC label remains trapped in the tubular cell. The rate of
a)
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Fig. 2. Renal time course of 123j and '311-TC radiolabeled cyto-
chrome-c (upper panel), lysozyme (middle panel) and aprotinin (lower
panel) after intravenous injection in 6 rats. Values are given as mean
SEM (shaded area). Regression lines (obtained by kinetic analyses) are
drawn, representing the rate of renal uptake (a) and renal degradation
(b) of the '231-LMWP. The degradation of cytochrome-c appeared to be
biphasic (b' and b"). Total amount of renal uptake is presented by the
extrapolated degradation curve of '231-LMWP to the time of injection
(A) and by the maximum level of radioactivity of '311-TC-LMWP (B).
uptake appears to be similar to the uptake kinetics of 1231..
LMWP. This indicates that the difference in the two labels does
not affect the renal uptake of the LMWP.
Total amount of renal LMWP
The total amount of renal uptake was obtained in two
different ways: first of all, by extrapolating the renal degrada-
tion curve of 1231-LMWP to the time of injection. This is
visualized in Figure 2 by the percentage of injected dose at time
zero on the regression line of degradation (A). Secondly, it was
found by estimating the renal accumulation of '311-TC-LMWP
at the plateau level (Fig. 2, visualized by the horizontal line to
time zero: B). The results are listed in Table 3. The data show
that the two methods are in good agreement for the proteins,
LMWP
Renal half-hfe t'/2 in mm
Uptake Degradation
Cytochrome-c
Lysozyme
Aprotinin
4.0 0.1
14.2 1.3
31.2 0.9
l'
2nd
11
222
252
443
1 (83 6%)
46 (17 1%)
26 (100%)
28 (100%)
Table 3. Total amount of renal uptake (% of injected dose) of
radiolabeled LMWPs after intravenous injection in 6 rat
LMWP
Renal uptake (%)
'231-LMWP '311-TC-LMWP
Cytochrome-c 89 4 (72—108) 88 5 (67—99)
Lysozyme 67 6 (49—84) 84 3 (77—98)
Aprotinin 78 2 (69—84) 79 3 (70—90)
Data are given as mean SEM (values in parenthesis denote the
range). Data are obtained by kinetic analysis of the renal time course of
123J and by estimating the stable maximum level of the renal 1311
radioactivity.
Degradation products
Plasma samples were analyzed for TCA-soluble radioactiv-
ity, representing the degradation products of the intravenous
injected radiolabeled LMWP. No detectable amounts of 131j
degradation products were found in the plasma, suggesting that
the 1311-TC label is indeed trapped in the cell in which it is
internalized. This is in contrast to the 123! degradation products,
of which the plasma appearance pattern (Fig, lB) seems to be in
agreement with the rate of LMWP degradation in the kidney
(Fig. 2). The urine accumulation of radioactivity was monitored
continuously by external counting. Subsequently, urine sam-
ples were analyzed for protein, amino acid bound and unbound
radioactivity by TCA precipitation and silver crystallization. As
in plasma, no detectable amounts of 1311-TC-degradation prod-
ucts were found in the urine. Figure 3 shows the accumulation
of the 123! degradation products in the urine. Since the kidney is
the major site of LMWP degradation, supposedly the 123!
degradation products in the urine are mainly originating from
the kidney. Indeed, the appearance of the 123j degradation
products in the urine appears to coincide with the renal disap-
pearance of 123j (Fig. 2). During the time of the study with
cytochrome-c, lysozyme and aprotinin, 73 3%, 61 2% and
43 3% of the injected 123! were released from the kidney,
respectively. In the same period 44 3% (Cy), 40 4% (Ly)
and 25 2% (Ap) of the injected dose of 123j were recovered as
Table 2. Renal kinetics of 1231-LMWP after intravenous injection in 6
rats
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Cytochrome-c Data are given as mean SEM. The t'/2 uptake is defined as the time
in which the renal content, after the first pass uptake, increases with
50%. The t½ degradation is the time in which 50% is released from the
kidney. Numbers in parenthesis denote the contribution of the different
degradation phases relative to the total renal degradation of the LMWP.
150 200 250
1-123
lysozyme
A13C
1-123
Aprotinin
cytochrome-c and aprotinin. For lysozyme, the 123! uptake data
are lower (P = 0.05) and exhibit more variation (49 to 84%)
compared to the 1311-TC results (77 to 98%). Striking is the
high and remarkably similar renal accumulation of the three
_______________________________________ LMWPs: 88, 84, 79% of the injected dose for '311-TC labeled
0 100 200 300 400 500 cytochrome-c, lysozyme and aprotinin, respectively.
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degradation products in the urine. This implies that 60% (Cy),
66% (Ly) and 59% (Ap) of the degradation products released
from the kidney during the time of the study were recovered in
the urine. This may be due to the large distribution volume of
the '231-breakdown products in the body. From these degrada-
tion products 67 5% (Cy), 73 5% (Ly) and 91 1% (Ap)
were bound to amino acids. The rest was free 1231 This
indicates that the efficiency of deiodinase inhibition by the MIT
was not complete and was different for the three LMWPs
studied. No detectable amounts of LMWP bound iodine were
found in the urine, suggesting that the injected tracer amounts
of LMWPs were maximally reab sorbed by the proximal tubular
cell.
Discussion
In the present study, we show that we can quantify both renal
uptake and degradation of a '231-radiolabeled LMWP in an
intact rat by registering the renal time-activity curve with a
gamma-camera and applying subsequent kinetic analysis to the
obtained curve.
The total amount of renal uptake was approximately 80% of
the administered dose for all the three LMWPs, cytochrome-c,
lysozyme and aprotinin. An accumulation up to 80% of the
injected dose is in good agreement with some of the studies in
the literature. First of all, our results are in line with the renal
extraction studies, which show 73% extraction for parathyroid
hormone [2], 67% for growth hormone {3] in rats, and 90% for
growth hormone in sheep [4]. However, such studies may show
considerable variability since they are based on a combination
of in vivo and kidney perfusion data [2, 3] or on measurements
of minute differences in protein concentrations in renal arterial
and venous blood [4]. Secondly, our uptake data match the 90%
contribution of the kidney in the catabolism of lambda- 1-chain
reported by Waldmann, Strober and Mogielnicki [5]. These
authors calculated this value using the metabolic rate of the
LMWP and the creatinine clearance in healthy individuals.
A more direct way to study the renal handling of LMWPs is
the measurement of the actual amount of LMWP in the kidney.
In spite of the similar experimental approach, most of such
studies suggest a markedly lower renal uptake and differences
among the various LMWPs compared to the 80% for all the
three LMWPs in the present study. What are the possible
explanations for these differences? Just, Christensen, Ottensen
and Bianchi et a! [6—9] injected iodinated LMWPS intravenously
in the rat and measured the radioactivity in extirpated kidneys
after different time intervals. Depending on both the LMWP
and on the time point with the highest radioactivity, 29 to 58%
of the injected dose was maximally recovered in the kidneys.
However, this renal radioactivity is likely to be an underesti-
mation of the total amount of LMWP uptake. First of all, it is
difficult to determine the exact time point on which the renal
amount is maximal. Bianchi et al solved this by establishing the
maximum beforehand by continuous external counting [9].
Secondly, the level of this "maximum" is determined by both
uptake and degradation of the LMWP in the kidney. In our
study with 1231-LMWP we bypassed these limitations, since our
kinetic analysis of uptake is based on correction for the renal
rate of degradation of the 1231-LMWP.
To validate the calculated amount of renal uptake of l23J
LMWP, we co-injected '311-TC-LMWP. Since the '311-TC label
remains trapped in the kidney cell, there will be no interference
with the renal degradation of the LMWP. This method was used
before by Hysing, Tolleshaug and Curthoys [10]. Compared to
us, they found the rather low renal uptake values of 43% for
cytochrome-c and 35% for lysozyme. Although we used the
same procedures of iodination and coupling, we did not detect
any radioactivity in the liver. This in contrast to their study in
which a hepatic accumulation of 19% of the injected dose was
found. Such an hepatic uptake may indicate denaturation or
aggregation of the protein. Besides this, other factors should be
considered like the anesthesia and the computation of the
amount of radioactivity in the extirpated kidney relative to the
administered dose. In our study, the reliability of the 1311-TC-
LMWP results largely depend on the proper corrections of the
gamma camera data. However, evidence that these corrections
did not significantly effect our uptake data is shown by the very
similar data of the separate study with '231-TC-lysozyme in
which no corrections were needed.
Apart from the total amount of renal uptake, we quantified
the rate of renal uptake and degradation of the LMWP. There is
a clear difference in the rate of renal uptake between the three
LMWPs. Differences in renal extraction appear not to explain
this phenomenon, since the renal clearance of the three
LMWPs are reported to be very similar and close to the
glomerular filtration rate [11. In this study, the renal clearance,
calculated from the renal rate of uptake and the distribution
volume, appeared to be about 1.9, 1.0 and 1.1 mllmin for
cytochrome-c, lysozyme and aprotinin, respectively. In agree-
ment with the literature, these data are indeed quite comparable
to one another and close to the glomerular filtration rate, which
makes it rather unlikely that the difference in renal extraction
explains the difference in rate of renal uptake. This leaves open
the option of a difference in extra-renal distribution volume
between the different LMWPs. Evidence for this option is
clearly shown by the difference in estimated distribution vol-
ume of the three LMWPs.
(i
ij)
11)
>
>
0
0
1)C
50
40
30
20
10
0
0 100 200 300 400 500
Time, minutes
Fig. 3. Time course of urinary excretion of '23j after intravenous
injection of 123j radiolabeled cytochrome-c, lysozyme and aprotinin in 6
rats. Values are given as mean SEM. More than 95% of the 1231
appeared to be TCA soluble, representing radiolabeled degradation
products. No 1311 was recovered in the urine.
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The renal rate of degradation of the three LMWPs, cyto-
chrome-c, lysozyme and aprotinin have not been quantified
before. The estimated data from the literature are in line with
our results. The rate of renal degradation of cytochrome-c is
high (within minutes) [7, 9, 11], of lysozyme intermediate [8, 9],
and of aprotinin low (several hours) [9].
In conclusion, we show that the renal handling of LMWPs
can be quantified non-invasively in the intact rat by applying
kinetic analysis on the renal time-activity curve of '231-labeled
LMWP, obtained with a gamma camera.
For the three tested LMWPs, cytochrome-c, lysozyme and
aprotinin the total amount of renal uptake is high (about 80%)
and strikingly similar, whereas their renal degradation rate is
quite different. The presented technique may not only be used
to extend our knowledge in renal LMWP handling in animal
experimental settings, but may also be of use in a clinical
environment.
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